RATIONALE FOR THE USE OF ANTI-DYSBIOTIC HEPATOPROTECTOR IN THE TREATMENT OF PATIENTS WITH INFLAMMATORY PERIODONTAL DISEASES ON THE BACKGROUND OF CHRONIC TOXIC HEPATITIS

Authors

  • A. I. Furdychko Lviv National Medical University named after Danylo Halytskij
  • V. Ia. Skiba State Etablishment «The Institute of Stomatology and Maxillo-Facial Surgery of the National Academy of Medical Science of Ukraine»
  • S. A. Schneider State Etablishment «The Institute of Stomatology and Maxillo-Facial Surgery of the National Academy of Medical Science of Ukraine»

Keywords:

hepatobiliary pathology, periodontal disease, inflammation, hepatitis, dysbiosis

Abstract

Periodontal disease often occurs on the background of the concomitant pathology of the hepatobiliary system. The intestinal dysbiosis hes negative effect on the hepatobiliary system, therefore the use of antidisbiotic medicines, that carry out hepatoprotective effects is appropriate. One of the means that possesses antidisbiotic properties and carries hepatoprotective effect is "Lecvin", which includes hepatoprotector lecithin, bioflavonoid quercetin, prebiotic inulin and calcium citrate.
The aim. Tto investigate the state of periodontal tissues in patients with chronic toxic hepatitis and to substantiate the proposed therapy.
The materials and methods. The study involved 94 patients with inflammatory diseases of the periodontium associated with chronic toxicity of hepatitis. In 46 people use basic therapy, and 48 people, in addition to basic therapy, included the anti-dysbiosis medicines "Lecvin". This drug was prescribed for 1-2 tablets 2-3 times daily after a meal, as well as patients every day performed oral applications "Lecvin" with gel by applying 0.52 ml (disposable pressure of the dispenser) to a thin layer of gum after meals 2-3 times per day.
The results. Use in the complex therapy of antidysbiotics medicines "Lekvin", improve the index of hygiene, the periodontal-marginal-alveolar index, and reduces the index of bleeding.
The conclusions. The effectiveness of using of antidisbiotic hepatoprotector in the treatment of patients with inflammatory diseases of the periodontal by the associated with chronic toxic hepatitis is confirmed not only by the disappearance of the clinical symptoms of the periodontal disease, but also the duration of a stable therapeutic effect (for half a year).

References

Левицкий А. П. Гепато-оральный синдром / А. П. Левицкий, С. А. Демьяненко. – Симферополь: Тарпан, 2012. 136 с.

Біохімічні показники запалення і дисбіозу в ротовій рідині (слині) хворих на гепато-біліарну патологію / В. М. Зубачик, Г.З. Борис, А. І. Фурдичко [та ін.] // Вісник

стоматології.– 2017. – №3. – С. 12-16.

Furdychko A. I. Clinical-laboratory justificationof de-pendence of periodontal inflammatory diseases on the condinion of hepatobiliary system / A. I. Furdychko, P.A. Hasiuk, V.V. Ivanchyshyn, N.V. Hasiuk // Світ медицини та біології. – 2018. – №1(63). – С. 87-89.

Патент на корисну модель Антидисбіотичний засіб Леквін № 108536 / А.П. Левицький, О.А. Макаренко, І. О. Селіванська [та ін.]. Заявка u 2015 12750 від 23.12.2015. Бюл. № 14 від 25.07.2016.

Мащенко И. С. Болезни пародонта / И. С. Мащенко. – Днепропетровск: КОЛО, 2003. – 272 с

Published

2021-05-28

How to Cite

Фурдичко, А. І., Скиба, В. Я., & Шнайдер, С. А. (2021). RATIONALE FOR THE USE OF ANTI-DYSBIOTIC HEPATOPROTECTOR IN THE TREATMENT OF PATIENTS WITH INFLAMMATORY PERIODONTAL DISEASES ON THE BACKGROUND OF CHRONIC TOXIC HEPATITIS. Stomatological Bulletin, 106(1), 46–49. Retrieved from http://visnyk.od.ua/index.php/mainjournal/article/view/91

Issue

Section

THERAPEUTIC SECTION

Most read articles by the same author(s)

1 2 > >>